Werewolf Therapeutics, Inc. Common Stock (HOWL) Stock Price
HOWLStock
$0.94−32.14%52W
Market Cap$45.84M
P/E—
PEG Ratio—
Div yield—
Beta0.56
HOWL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)30.65%
Price vs S&P 500 (4W)155.07%
VGM Score72.47
HOWL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.32 | $0.14 | +145.16%(+$0.46) | |
| Q1 2026 | -$0.29 | -$0.28 | +5.08%(+$0.01) | |
| Q4 2025 | -$0.35 | -$0.17 | +50.96%(+$0.18) | |
| Q3 2025 | -$0.38 | -$0.36 | +5.88%(+$0.02) | |
| Q2 2025 | -$0.37 | -$0.40 | -7.14%(-$0.03) |
HOWL Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HOWLWerewolf Therapeutics, Inc. Common Stock | — | — | B | $0.94 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Werewolf Therapeutics, Inc. Common Stock
Werewolf Therapeutics develops cancer immunotherapies using its proprietary PREDATOR platform to engineer conditionally activated molecules. The company's INDUKINE molecules remain inactive in healthy tissue but selectively activate immune responses within the tumor microenvironment, potentially addressing the side-effect limitations of conventional immunotherapies. This targeted approach aims to combine improved therapeutic efficacy with reduced systemic toxicity.